Area of research
Genetics · Pulmonary and Respiratory Medicine
Research interest
Research interests include Glioma Diagnosis and Treatment, Meningioma and schwannoma management, Nanoplatforms for cancer theranostics, and Photodynamic Therapy Research Studies.
Localization of protoporphyrin IX during glioma-resection surgery via paired stimulated Raman histology and fluorescence microscopy
Insights from a multicenter study on adult H3 K27M-mutated glioma: Surgical resection’s limited influence on overall survival, ATRX as molecular prognosticator
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomide
Single-cell transcriptomics link gene expression signatures to clinicopathological features of gonadotroph and lactotroph PitNET
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
Telemedicine in Neuro-Oncology—An Evaluation of Remote Consultations during the COVID-19 Pandemic
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed <i>MGMT</i> promoter methylated <i>IDH</i> wildtype glioblastoma
TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma
Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
5-ALA and FDA approval for glioma surgery
EANO–EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma
FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma
Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis
Randomized, Prospective Double-Blinded Study Comparing 3 Different Doses of 5-Aminolevulinic Acid for Fluorescence-Guided Resections of Malignant Gliomas
Shifting cancer care towards Multidisciplinarity: the cancer center certification program of the German cancer society
Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07)
ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma
Neuroonkologische Zentren (NOZ)
P16.11 Complete resection is not associated with improved survival in MGMT non-methylated glioblastoma. Results from the GLARIUS trial
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O<sup>6</sup>-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial
What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas?
Predicting the “usefulness” of 5-ALA-derived tumor fluorescence for fluorescence-guided resections in pediatric brain tumors: a European survey
QL-13 * QUALITY OF LIFE AND COGNITIVE FUNCTIONING IN THE RANDOMIZED, MULTICENTER GLARIUS TRIAL INVESTIGATING BEVACIZUMAB/IRINOTECAN VS STANDARD TEMOZOLOMIDE IN NEWLY DIAGNOSED, MGMT-NON-METHYLATED GLIOBLASTOMA PATIENTS
5-Aminolevulinic Acid-derived Tumor Fluorescence
MEDICAL RADIATION THERAPIES